O	0	1	A
O	2	12	Comparison
O	13	15	of
B-intervention	16	24	Fentanyl
I-intervention	25	28	and
I-intervention	29	41	Flurbiprofen
I-intervention	42	48	Axetil
O	49	51	on
O	52	57	Serum
O	58	62	VEGF
O	62	63	-
O	63	64	C
O	64	65	,
O	66	69	TNF
O	69	70	-
O	70	71	α
O	71	72	,
O	73	76	and
O	77	79	IL
O	79	80	-
O	80	81	1
O	81	82	ß
O	83	97	Concentrations
O	98	100	in
O	101	106	Women
O	107	117	Undergoing
O	118	125	Surgery
O	126	129	for
O	130	136	Breast
O	137	143	Cancer
O	143	144	.

O	145	153	Vascular
O	154	165	endothelial
O	166	172	growth
O	173	179	factor
O	179	180	-
O	180	181	C
O	182	183	(
O	183	187	VEGF
O	187	188	-
O	188	189	C
O	189	190	)
O	190	191	,
O	192	197	tumor
O	198	206	necrosis
O	207	213	factor
O	213	214	-
O	214	215	α
O	216	217	(
O	217	220	TNF
O	220	221	-
O	221	222	α
O	222	223	)
O	223	224	,
O	225	228	and
O	229	240	interleukin
O	240	241	-
O	241	242	1
O	242	243	ß
O	243	244	(
O	244	246	IL
O	246	247	-
O	247	248	1
O	248	249	ß
O	249	250	)
O	251	255	have
O	256	260	been
O	261	266	shown
O	267	269	to
O	270	272	be
O	273	283	associated
O	284	288	with
O	289	292	the
O	293	303	recurrence
O	304	307	and
O	308	318	metastasis
O	319	321	of
O	322	328	breast
O	329	335	cancer
O	336	341	after
O	342	349	surgery
O	349	350	.

O	351	355	This
O	356	361	study
O	362	368	tested
O	369	372	the
O	373	383	hypothesis
O	384	388	that
O	389	397	patients
O	398	408	undergoing
O	409	416	surgery
O	417	420	for
O	421	427	breast
O	428	434	cancer
O	434	435	,
O	436	439	who
O	440	448	received
O	449	462	postoperative
O	463	472	analgesia
O	473	477	with
O	478	490	flurbiprofen
O	491	497	axetil
O	498	506	combined
O	507	511	with
O	512	517	small
O	518	523	doses
O	524	526	of
O	527	535	fentanyl
O	536	537	(
O	537	539	FA
O	539	540	)
O	540	541	,
O	542	551	exhibited
O	552	559	reduced
O	560	566	levels
O	567	569	of
O	570	574	VEGF
O	574	575	-
O	575	576	C
O	576	577	,
O	578	581	TNF
O	581	582	-
O	582	583	α
O	583	584	,
O	585	588	and
O	589	591	IL
O	591	592	-
O	592	593	1
O	593	594	ß
O	595	603	compared
O	604	608	with
O	609	614	those
O	615	623	patients
O	624	633	receiving
O	634	642	fentanyl
O	643	648	alone
O	649	650	(
O	650	651	F
O	651	652	)
O	652	653	.

B-total-participants	654	659	Forty
O	659	660	-
B-eligibility	660	665	women
I-eligibility	666	670	with
I-eligibility	671	678	primary
I-eligibility	679	685	breast
I-eligibility	686	692	cancer
I-eligibility	693	703	undergoing
I-eligibility	704	705	a
I-eligibility	706	714	modified
I-eligibility	715	722	radical
I-eligibility	723	733	mastectomy
O	734	738	were
O	739	749	randomized
O	750	752	to
O	753	760	receive
O	761	774	postoperative
O	775	784	analgesia
O	785	789	with
O	790	802	flurbiprofen
O	803	809	axetil
O	810	818	combined
O	819	823	with
O	824	832	fentanyl
O	833	835	or
B-control	836	844	fentanyl
I-control	845	850	alone
O	850	851	.

O	852	858	Venous
O	859	864	blood
O	865	868	was
O	869	876	sampled
O	877	883	before
O	884	894	anesthesia
O	894	895	,
O	896	898	at
O	899	902	the
O	903	906	end
O	907	909	of
O	910	917	surgery
O	917	918	,
O	919	922	and
O	923	925	at
O	926	928	48
O	929	934	hours
O	935	940	after
O	941	948	surgery
O	948	949	,
O	950	953	and
O	954	957	the
O	958	963	serum
O	964	967	was
O	968	976	analyzed
O	976	977	.

O	978	981	The
O	982	989	primary
O	990	998	endpoint
O	999	1002	was
B-outcome-Measure	1003	1010	changes
I-outcome-Measure	1011	1013	in
I-outcome-Measure	1014	1017	the
I-outcome-Measure	1018	1022	VEGF
I-outcome-Measure	1022	1023	-
I-outcome-Measure	1023	1024	C
I-outcome-Measure	1025	1039	concentrations
I-outcome-Measure	1040	1042	in
I-outcome-Measure	1043	1048	serum
O	1048	1049	.

O	1050	1055	Group
O	1056	1058	FA
O	1059	1067	patients
O	1068	1076	reported
O	1077	1084	similar
B-outcome	1085	1094	analgesic
I-outcome	1095	1102	effects
O	1103	1105	as
O	1106	1111	group
O	1112	1113	F
O	1114	1122	patients
O	1123	1125	at
O	1126	1127	2
O	1127	1128	,
O	1129	1131	24
O	1131	1132	,
O	1133	1136	and
O	1137	1139	48
O	1140	1145	hours
O	1145	1146	.

O	1147	1149	At
O	1150	1152	48
O	1153	1158	hours
O	1158	1159	,
B-outcome	1160	1164	mean
I-outcome	1165	1178	postoperative
I-outcome	1179	1193	concentrations
I-outcome	1194	1196	of
I-outcome	1197	1201	VEGF
I-outcome	1201	1202	-
I-outcome	1202	1203	C
O	1204	1206	in
O	1207	1212	group
O	1213	1214	F
O	1215	1223	patients
O	1224	1228	were
O	1229	1235	higher
O	1236	1240	than
O	1241	1243	in
O	1244	1249	group
O	1250	1252	FA
O	1253	1261	patients
O	1261	1262	,
B-iv-cont-mean	1263	1266	730
I-iv-cont-mean	1266	1267	.
I-iv-cont-mean	1267	1268	9
O	1269	1275	versus
O	1275	1276	.

B-cv-cont-mean	1277	1280	354
I-cv-cont-mean	1280	1281	.
I-cv-cont-mean	1281	1282	1
I-cv-cont-mean	1283	1285	pg
I-cv-cont-mean	1285	1286	/
I-cv-cont-mean	1286	1288	mL
O	1289	1290	(
O	1290	1291	P
O	1292	1293	=
O	1294	1295	0
O	1295	1296	.
O	1296	1299	003
O	1299	1300	)
O	1300	1301	,
O	1302	1314	respectively
O	1314	1315	.

O	1316	1319	The
B-outcome	1320	1324	mean
I-outcome	1325	1338	postoperative
I-outcome	1339	1353	concentrations
I-outcome	1354	1356	of
I-outcome	1357	1360	TNF
I-outcome	1360	1361	-
I-outcome	1361	1362	α
O	1363	1365	in
O	1366	1371	group
O	1372	1373	F
O	1374	1382	patients
O	1383	1387	were
O	1388	1392	also
O	1393	1399	higher
O	1400	1408	compared
O	1409	1413	with
O	1414	1419	group
O	1420	1422	FA
O	1423	1431	patients
B-iv-cont-mean	1432	1434	27
I-iv-cont-mean	1434	1435	.
I-iv-cont-mean	1435	1436	1
O	1437	1439	vs
O	1439	1440	.
B-cv-cont-mean	1441	1443	15
I-cv-cont-mean	1443	1444	.
I-cv-cont-mean	1444	1445	8
I-cv-cont-mean	1446	1448	pg
I-cv-cont-mean	1448	1449	/
I-cv-cont-mean	1449	1451	mL
O	1452	1453	(
O	1453	1454	P
O	1455	1456	=
O	1457	1458	0
O	1458	1459	.
O	1459	1462	005
O	1462	1463	)
O	1463	1464	.

O	1465	1472	Finally
O	1472	1473	,
O	1474	1477	the
B-outcome	1478	1482	mean
I-outcome	1483	1496	postoperative
I-outcome	1497	1511	concentrations
I-outcome	1512	1514	of
I-outcome	1515	1517	IL
I-outcome	1517	1518	-
I-outcome	1518	1519	1
I-outcome	1519	1520	ß
O	1521	1523	in
O	1524	1529	group
O	1530	1531	F
O	1532	1536	were
O	1537	1541	also
O	1542	1555	significantly
O	1556	1562	higher
O	1563	1567	than
O	1568	1570	in
O	1571	1576	group
O	1577	1579	FA
B-iv-cont-mean	1580	1583	497
I-iv-cont-mean	1583	1584	.
I-iv-cont-mean	1584	1585	5
O	1586	1588	vs
O	1588	1589	.
B-cv-cont-mean	1590	1593	197
I-cv-cont-mean	1593	1594	.
I-cv-cont-mean	1594	1595	7
I-cv-cont-mean	1596	1598	pg
I-cv-cont-mean	1598	1599	/
I-cv-cont-mean	1599	1601	mL
O	1602	1603	(
O	1603	1604	P
O	1605	1606	=
O	1607	1608	0
O	1608	1609	.
O	1609	1612	001
O	1612	1613	)
O	1613	1614	.

O	1615	1617	In
O	1618	1626	patients
O	1627	1637	undergoing
O	1638	1639	a
O	1640	1650	mastectomy
O	1650	1651	,
O	1652	1665	postoperative
O	1666	1675	analgesia
O	1676	1680	with
O	1681	1693	flurbiprofen
O	1694	1700	axetil
O	1700	1701	,
O	1702	1710	combined
O	1711	1715	with
O	1716	1724	fentanyl
O	1724	1725	,
O	1726	1730	were
O	1731	1741	associated
O	1742	1746	with
O	1747	1756	decreases
O	1757	1759	in
O	1760	1765	serum
O	1766	1780	concentrations
O	1781	1783	of
O	1784	1788	VEGF
O	1788	1789	-
O	1789	1790	C
O	1790	1791	,
O	1792	1795	TNF
O	1795	1796	-
O	1796	1797	α
O	1797	1798	,
O	1799	1802	and
O	1803	1805	IL
O	1805	1806	-
O	1806	1807	1
O	1807	1808	ß
O	1809	1817	compared
O	1818	1822	with
O	1823	1831	patients
O	1832	1841	receiving
O	1842	1847	doses
O	1848	1850	of
O	1851	1855	only
O	1856	1864	fentanyl
O	1864	1865	.
